Cargando…

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs

Peroxisome proliferator-activator receptor (PPAR) γ is a nuclear hormone receptor that regulates glucose homeostasis, lipid metabolism, and adipocyte function. PPARγ is a target for thiazolidinedione (TZD) class of drugs which are widely used for the treatment of type 2 diabetes. Recently, lobeglita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Min A, Tan, Lingchen, Yang, Huiseon, Im, Yeong-Gwan, Im, Young Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715099/ https://www.ncbi.nlm.nih.gov/pubmed/29203903 http://dx.doi.org/10.1038/s41598-017-17082-x

Ejemplares similares

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Targeting PPAR-γ to design and synthesize antidiabetic thiazolidines
por: Sawant, Ramesh L., et al.
Publicado: (2018)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
por: Lee, Yu Seol, et al.
Publicado: (2018)

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
por: Swanson, Christine R, et al.
Publicado: (2011)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Structure of human ORP3 ORD reveals conservation of a key function and ligand specificity in OSBP-related proteins
por: Tong, Junsen, et al.
Publicado: (2021)

Effects of Pioglitazone Mediated Activation of PPAR-γ on CIDEC and Obesity Related Changes in Mice
por: Shamsi, Bilal Haider, et al.
Publicado: (2014)

Diet Modifies Pioglitazone's Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression
por: Kulkarni, Sakil, et al.
Publicado: (2020)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
por: Amin, Fatemeh, et al.
Publicado: (2021)

Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells
por: Esmaeili, Shadi, et al.
Publicado: (2021)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Effects of PPARγ Agonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats
por: Dovinová, Ima, et al.
Publicado: (2013)

Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial
por: Anderson, J. R., et al.
Publicado: (2016)

Pioglitazone, a PPAR-γ Activator, Stimulates BK(Ca) but Suppresses IK(M) in Hippocampal Neurons
por: Chen, Tsang-Shan, et al.
Publicado: (2018)

Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
por: Ramirez-Moral, Ivan, et al.
Publicado: (2021)

Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer
por: Tashiro, Yoshihiko, et al.
Publicado: (2020)

Retraction Note: Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
por: Amin, Fatemeh, et al.
Publicado: (2022)

The PPAR-γ Agonist Pioglitazone Modulates Proliferation and Migration in HUVEC, HAOSMC and Human Arteriovenous Fistula-Derived Cells
por: Ciavarella, Carmen, et al.
Publicado: (2023)

A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids
por: Al-Arfaj, Nawal Ahmad, et al.
Publicado: (2008)

Molecular recognition of nitrated fatty acids by PPARγ
por: Li, Yong, et al.
Publicado: (2008)

Pioglitazone Reduces β Amyloid Levels via Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer’s Disease
por: Quan, Qiankun, et al.
Publicado: (2019)

The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3
por: Németh, Ágnes, et al.
Publicado: (2019)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex
por: Lemkul, Justin A., et al.
Publicado: (2015)

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
por: Yasmin, Sabina, et al.
Publicado: (2017)

Insulin Sensitization by PPARγ and GLUT-4 Overexpression/Translocation Mediates the Antidiabetic Effect of Plantago australis †
por: Estrada-Soto, Samuel, et al.
Publicado: (2023)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

Pparγ2 Is a Key Driver of Longevity in the Mouse
por: Argmann, Carmen, et al.
Publicado: (2009)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
por: Namvaran, Fatemeh, et al.
Publicado: (2013)

Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
por: Mottaghi, Peyman
Publicado: (2013)

Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice
por: Kurhe, Yeshwant, et al.
Publicado: (2016)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
por: Liu, Chi-Hung, et al.
Publicado: (2020)

Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
por: Teixeira, Catarina, et al.
Publicado: (2022)

Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple
por: Yuan, Liyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7sngiv0obga777qlcfih6ho24u